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Abstract
Objective We propose a Magnetic Resonance Imaging (MRI)
guided approach to differential diagnosis of ovarian tumours
based on morphological appearance.
Background Characterization of ovarian lesions is of great
importance in order to plan adequate therapeutic procedures,
and may influence patient’s management. Optimal assessment
of adnexal masses requires a multidisciplinary approach,
based on physical examination, laboratory tests and imaging
techniques. Primary ovarian tumours can be classified into
three main categories according to tumour origin: epithelial,
germ cell and sex cord-stromal tumours. Ovarian neoplasms
may be benign, borderline or malignant. Using an imaging-
guided approach based on morphological appearance, we
classified adnexal masses into four main groups: unilocular
cyst, multilocular cyst, cystic and solid, predominantly solid.
We describe MR signal intensity features and enhancement
behaviour of ovarian lesions using pathologically proven ex-
amples from our institution.
Conclusion MRI is an essential problem-solving tool to de-
termine the site of origin of a pelvic mass, to characterize an
adnexal mass, and to detect local invasion. The main advan-
tages of MRI are the high contrast resolution and lack of
ionizing radiation exposure. Although different pathological
conditions may show similar radiologic manifestations, radi-
ologists should be aware of MRI features of ovarian lesions
that may orientate differential diagnosis.
Teaching Points
• Diagnostic imaging plays a crucial role in detection, char-
acterization and staging of adnexal masses.
• Characterization of an ovarian lesion may influence pa-
tient’s management.
• Different pathological conditions may have similar radio-
logic manifestations.
• Non-neoplastic lesions should always be taken into
consideration.
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Introduction
Ovarian masses are a common finding in daily clinical prac-
tice and may be incidentally detected or identified in symp-
tomatic patients. Characterization of an ovarian lesion repre-
sents a diagnostic challenge; it is of great importance in the
preoperative setting in order to plan adequate therapeutic pro-
cedures and may influence patient’s management.
Magnetic resonance (MR) imaging may provide useful in-
formation for the characterization of ovarian masses as non-
neoplastic or neoplastic, and, in the latter case, as benign or
malignant. Therefore, radiologists play an important role in
the multidisciplinary approach of ovarian mass, and, though
different pathological conditions may have similar radiologic
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manifestations, they should be aware of MR imaging features
of ovarian lesions that may orientate the differential diagnosis.
In this article, we review epidemiology, etiopathogenesis,
classification, staging and diagnostic approaches to ovarian
masses. We propose an MR imaging-guided approach to the
differential diagnosis of ovarian tumours based on morpho-
logical appearance. We describe MR signal intensity features
(e.g., haemorrhagic areas, elevated protein content, fat and
collagenous tissue) and enhancement behaviour of each lesion
using pathologically proven examples from our institution.
Our MR protocol is also included.
Epidemiology
Ovarian cancer is currently one of the most common forms of
cancer among women worldwide, responsible for 3.6 % of all
cases, with a mortality of 4.3 %. In Europe, it is the leading
cause of cancer death among gynaecologic malignancies,
ranking fifth in incidence (exceeded only by breast,
colorectum, lung and corpus uteri) and sixth in mortality
among all women’s cancer (exceeded by breast, colorectum,
lung, pancreas and stomach) [1]. An important reason for the
high mortality rates of this cancer is the late diagnosis. Many
patients present in advanced stage, mostly because the disease
is often asymptomatic or associated with nonspecific symp-
toms in the early stage. Incidental detection of adnexal mass is
very common in clinical practice.
Etiopathogenesis
Etiopathogenesis of ovarian tumours is not fully understood;
however, it appears to be multifactorial. The leading risk fac-
tor is familiarity; namely, history of ovarian cancer in a first-
degree relative. However, only 5–10 % of cases are related to
hereditary syndromes: the main one is the breast-ovarian can-
cer syndrome, due to mutations in the BRCA1 and BRCA2
tumour suppressor genes. Approximately 90–95 % of cases
are sporadic, with an increasing risk related to nulliparity,
early menarche and late menopause, while pregnancy, lacta-
tion, early menopause and use of oral contraceptives appear to
be protective factors [2]. Hereditary cases occur predominant-
ly in premenopausal age, while the sporadic ones affect mostly
older women.
Classification
Primary ovarian tumours can be classified into three main
categories according to tumour origin: epithelial, germ cell
and sex cord-stromal tumours; ovaries are also affected by
metastastic tumours (Table 1) [3]. Epithelial tumours account
for approximately 85% of ovarian malignancy: the most com-
mon type is serous carcinoma. Dermoid cyst (mature cystic
teratoma) is the most common benign ovarian neoplasm. Sex
cord-stromal neoplasms may produce hormones, both
oestrogen and androgens, resulting in endocrinological symp-
toms. Ovarian neoplasms may be benign, borderline or malig-
nant. In addition, several benign lesions should also be con-
sidered, namely functional and haemorrhagic cyst, as well as
endometriomas.
Staging
There are two staging systems to describe the spread of
ovarian tumours: the TNM (tumour, node, metastasis) and
the International Federation of Gynecology and Obstetrics
(FIGO). The FIGO system has been recently revised and
went into effect on 1 January 2014 (Table 2). Basically,
stage I describes tumours confined to ovaries, stage II
reflects pelvic extension or primary peritoneal cancer,
stage III indicates spread to the peritoneum outside the
pelvis and/or metastasis to the retroperitoneal lymph
nodes, while stage IV refers to distant metastasis. Ovarian
cancer may show direct extension to surrounding pelvic
structures, as well as intraperitoneal, lymphatic and hema-
togenous spread. Local invasion of uterus, fallopian tubes
and contralateral adnexa can be found, while the involve-
ment of bladder and rectum is less frequent. One of the
most important features of ovarian cancer is intraperitone-
al dissemination by exfoliation of cells, often associated
with a variable amount of ascites: pouch of Douglas,
greater omentum and subphrenic region are the most com-
mon sites of implantation, probably because of the pref-
erential circulatory path of peritoneal fluid. Lymphatic
dissemination is most common to para-aortic and
paracaval lymph nodes, following the ovarian veins; path-
ologic lymph nodes can also be found in pelvic (external
iliac, hypogastric and obturatory) and inguinal chains. In-
cidence of lymph node metastasis has been estimated to
be about 25 % in stage I patients, about 50 % in patients
with stage II disease and about 74 % in advanced stages.
In addition, in patients with intraperitoneal disseminated
disease, there is a possibility of approximately 30 % of
pelvic, para-aortic or inguinal lymph nodes involvement
[4]. Hematogenous metastases are less frequent and most
often tend to involve liver and lung; however spleen,
bone, brain and other locations may be affected.
Approach to adnexal masses
The optimal assessment of an adnexal mass requires a multi-
disciplinary approach, based on physical examination, labora-
tory tests and imaging techniques. An important issue to con-
sider in the management of ovarian masses is that they are
very common, but most of them are benign and only a small
part is borderline ormalignant. Preoperative biopsy should not
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be performed in ovarian masses, particularly if the mass ap-
pears to be surgically resectable at the moment, as this inva-
sive procedure raises the risk of spreading cancer cells and
potentially leads to iatrogenic upstaging worsening the
prognosis.
Serum markers
The most commonly used serum tumour marker for epithelial
tumours is cancer antigen (CA)-125. In postmenopausal wom-
en, CA-125 has high sensitivity as well as high specificity,
while in premenopausal women, it has an high sensitivity
but low specificity, because it may also be elevated in other
conditions (e.g., peritoneal inflammation, endometriosis, etc.).
Human epididymis protein 4 (HE4) is a recently added tumour
marker and several studies have shown his usefulness in dis-
criminating between benign and malignant adnexal masses in
premenopausal women [5, 6].
Diagnostic imaging
Diagnostic imaging plays a crucial role in detection, charac-
terization and staging of adnexal masses.
Ultrasound (US) is often the first imaging study performed
in the evaluation of a suspected ovarian lesion because it’s
widely available, well accepted by patients, non-invasive
and of low cost. A combination of greyscale and colour Dopp-
ler features, obtained with transabdominal and/or endovaginal
scanning, allow for investigation of both morphological struc-
ture and vascular organization of the ovarian mass. Morpho-
logical features suggestive of malignancy include thickness
(>2–3 mm) and irregularity of walls and septa, the presence
of solid areas and papillary projections, as well as other evi-
dence ofmalignant activity, namely ascites, peritoneal nodules
and metastatic lesions. Regarding the vascularization, colour
Doppler study is able to demonstrate both the presence and the
localization of new tumour blood vessel: a predominantly
central blood flow is more often associated with malignancy,
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while a peripheral one is more typical of a benign lesion [7]. In
an ultrasound-indeterminate adnexal mass, Doppler ultra-
sound has shown a sensitivity of 84 % and a specificity of
82 % in diagnosing cancer [8]. Wu et al., on a recent meta-
analysis of ten independent studies, reported a high diagnostic
accuracy of contrast-enhanced ultrasound in distinguishing
between benign and malignant ovarian masses [9]. However,
unless morphological and vascularity features clearly indicate
a benign lesion, further assessment is mandatory. Levine et al.,
in a consensus statement (2009) for the Society of Radiolo-
gists in Ultrasound, made recommendations about manage-
ment of adnexal masses: BAdnexal masses in the physiologic
range in terms of size and appearance in a woman ofmenstrual
age or a simple adnexal cyst less than or equal to 1 cm in a
postmenopausal woman are likely benign; these findings are
almost always of no clinical importance in asymptomatic
women and can be safely ignored^ [10].
Computed Tomography (CT) of the abdomen and pelvis
after contrast administration is important both in evaluation
of spread of malignant lesions and in detection of recurrence
after therapy, whereas it has a limited value in primary detec-
tion and characterization of an ovarian mass. With CT scans,
only lesions containing fat tissue and calcifications, like ma-
ture teratoma, can be easi ly character ized. In a
sonographically indeterminate adnexal mass, CT has shown
a sensitivity of 81 % and a specificity of 87 % in ovarian
cancer diagnosis [8]. CT is the imaging technique of choice
in staging: looking for omental and peritoneal implants,
ascites and lymphadenopathy is very important to assess the
extension of the disease [8]. Therapy response evaluation is
usually performed with CT, comparing pre-treatment with
post-treatment scans (preferably after six cycles of chemother-
apy). An interval between the CTscans of only three cycles of
chemotherapy is indicated if serum markers are negative or
their levels are not decreasing [11].
18F-FDG PET/CT is being increasingly used and its role in
the evaluation of ovarian tumours appears to be crucial in the
postoperative follow-up of patients with suspected recurrence
[8, 12]. This imaging modality demonstrated a sensitivity of
up to 91 % and a specificity up to 100 % in the detection of
cancer recurrence, and plays a crucial role especially when CT
scans are negative but serummarker levels increase [11]. PET/
CT is not usually performed in the initial evaluation of these
patients, mostly because it may lead both to false-positive and
false-negative results. It has to be considered that several be-
nign lesions, particularly teratomas and endometriomas, may
show FDG uptake, whereas small (<1 cm), necrotic and low-
grade tumour may not [4]. However, finding an increased
FDG uptake in postmenopausal women has always to be con-
sidered an abnormality.
Magnetic Resonance Imaging (MRI) is an essential prob-
lem solving tool to determine the site of origin of a pelvic mass
and then to characterize an adnexal mass, especially in pa-
tients with indeterminate lesions [13, 14]. MRI is also reliable
in detecting local invasion. The main advantages of MRI are
the high contrast resolution with excellent soft tissue contrast
Table 2 FIGO system for ovarian cancer staging
Stage I Tumour confined to ovaries
I A Tumour limited to 1 ovary, capsule intact, no tumour on surface, negative washings
I B Tumour involves both ovaries otherwise like IA
I C Tumour limited to 1 or both ovaries
I C1 Surgical spill
I C2 Capsule rupture before surgery or tumour on ovarian surface
I C3 Malignant cells in the ascites or peritoneal washings
Stage II Tumour involves 1 or both ovaries with pelvic extension (below the pelvic brim) or primary peritoneal cancer
II A Extension and/or implant on uterus and/or Fallopian tubes
II B Extension to other pelvic intraperitoneal tissues
Stage III Tumour involves one or both ovaries with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or
metastasis to the retroperitoneal lymph nodes
III A Positive retroperitoneal lymph nodes and /or microscopic metastasis beyond the pelvis
III A1 Positive retroperitoneal lymph nodes only
III A2 Microscopic, extrapelvic (above the brim) peritoneal involvement ± positive retroperitoneal lymph nodes
III B Macroscopic, extrapelvic, peritoneal metastasis ≤2 cm ± positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen
III C Macroscopic, extrapelvic, peritoneal metastasis >2 cm ± positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen
Stage IV Distant metastasis excluding peritoneal metastasis
IVA Pleural effusion with positive cytology
IV B Hepatic and/or splenic parenchymal metastasis, metastasis to extraabdominal organs (including inguinal lymph nodes and lymph nodes
outside of the abdominal cavity)
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and lack of ionizing radiation exposure, which is particularly
important in young female patients.
In order to obtain anatomic information and to study mor-
phological and signal intensity characteristics of the mass,
both T1- and T2-weighted sequences are needed. Fat-
saturated T1-weighted images are helpful to detect
haemorrhagic areas and fat tissue. The use of intravenous
gadolinium improves detection of enhancing septa and solid
components within the mass and of peritoneal and omental
implants.
In the evaluation of adnexal masses indeterminate on ultra-
sound, unenhanced MRI has shown a sensitivity and a spec-
ificity of 76 and 97%, respectively, in the diagnosis of ovarian
cancer; assessment with contrast-enhanced MRI increases
sensitivity to 81 % and specificity to 98 % [8].
Diffusion-weighted imaging (DWI) is a potentially useful
technique in the assessment of adnexal masses; however, its
role has been controversial in literature. For Katayama et al.
[15] and Fujii et al., [16], DWI respectively Bis not useful^ and
Bprovide no additional information^ in discriminating benign
from malignant ovarian masses. In 2009, Thomassin-Naggara
et al. demonstrated that the combination of diffusion-weighted
and T2-weighted images is helpful in predicting benignity and
malignancy: masses with low signal intensity on both se-
quences were more likely benign, while lesions with high
signal intensity on DWI and intermediate signal on T2-
weighted images were more likely malignant [17]. Recently,
other studies [18, 19] have shown that high signal intensity on
DWI is more frequent within malignant lesions and is useful
for differentiating them from benign ones. It has to be consid-
ered that several benign lesions, namely endometriomas, ter-
atomas and fibrothecomas, may also show restricted diffusion;
however, a confident diagnosis of these lesions can usually be
done with T1-weighted, T1-weighted fat-suppressed and T2-
weighted standard sequences [20]. In a paper published in
2010, Kyriazi et al. investigated the role of DWI in the imag-
ing of peritoneal carcinomatosis in patients with advanced
ovarian cancer, showing that it could be helpful in the assess-
ment of volume and location of disease sites, as well as in
monitoring recurrence [21]. In 2014, Zhao et al. demonstrated
that DWI is useful in the differentiation of borderline and
malignant epithelial ovarian tumours [22]. In our opinion,
diffusion-weighted images should be included in MRI
protocol.
The role of 1.5 T MRI in the assessment of ovarian masses
has been widely established, but only in recent years have 3 T
MR systems been applied in the study of gynaecologic
diseases.
As for the magnetic field strength, the main advantage of
3 T MR systems is the expected increase in MR signal-to-
noise ratio (SNR) of up to twofold as compared with standard
1.5 T MR scanners; this gain in SNR can be used to improve
either speed or spatial resolution, or both. Nevertheless pulse
sequence parameters at 3 T need to be reoptimized from 1.5 T
values in order to maintain desired image contrast. Image
artefacts due to changes in tissue susceptibility, chemical shift,
radiofrequency effects, and/or pulse sequence physics may be
more noticeable and harder to suppress at 3 T [23]. In partic-
ular, DWI sequences can suffer from increased warping and
susceptibility artefacts at 3 T [23]. Previous studies [24] have
shown that when body DWMRI protocols are transferred
from 1.5 to 3 T without further modifications, image quality
is seriously degraded and images suffer from severe distor-
tions and signal losses, so qualitative assessment and quanti-
tative analysis can be problematic. Therefore, protocol adjust-
ment at 3 T is mandatory because compromised image quality
may have serious implications in diagnosis.
Proton MR spectroscopy is a non-invasive diagnostic tool
that may contribute to the differential diagnosis of subtypes in
ovarian tumours. In addition to the 1.5 T system, the superior
spectral separation and increased signal-to-noise ratio offered
by 3 T systems allow high quality MR spectroscopy. The
various subtypes of malignant epithelial ovarian tumours (se-
rous, clear cell, endometrioid, and mucinous) respond differ-
ently to chemotherapy. In particular, serous adenocarcinoma
may have a good response to chemotherapy, whereas clear cell
and mucinous adenocarcinomas may show poor response to
chemotherapy. Proton MR spectroscopy may identify the
presence of mucinous material containing N-acetyl mucinous
compounds, and can provide helpful information in
distinguishing mucinous and nonmucinous ovarian tumours.
Therefore, MR spectroscopy helps to diagnose the subtypes of
ovarian tumours andmay contribute to the adequate treatment,
thus improving management of these patients [25].
Compared with 1.5 T, the increased signal-to-noise ratio
and improved background suppression at 3 Tmay allow better
categorization of variable components (fluid, blood, lipid,
etc.). In addition, in the study of complex adnexal masses,
dynamic contrast-enhanced MRI is especially effective for
increasing the conspicuity of findings that are predictive of
malignancy. Owing to its higher diagnostic performance, 3 T
MRIs categorize and characterize the primary adnexal lesions
well, and could be regarded as a reliable non-invasive modal-
ity method for distinguishing malignancies from benign tu-
mours, though histological examination is needed to deter-
mine the final diagnosis [26].
Our MR protocol
The MR imaging protocol we use in our institution to study
patients with ovarian masses is as follows.
MR imaging is performed with a closed-configuration
superconducting 1.5-T system (Signa HDxT; GE Healthcare,
Milwaukee, Wis) with 57.2 mT/m gradient strength and
120 T/m/s slew rate, by using an eight-channel high-resolution
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torso coil with array spatial sensitivity technique (ASSET)
parallel acquisition.
MR sequences
– Localizer sequence in the three spatial planes;
– axial T2-weighted single-shot fast spin-echo (SSFSE) se-
quence [time to repetition (TR)/time to echo (TE) range
765/59; flip angle 90°; section thickness 6 mm; interslice
gap 0.6 mm; bandwidth 31.25 kHz; field of view (FOV)
38 cm; matrix 320×288; number of averages 0.54; num-
ber of images 30; acquisition time 24 s] used as second
localiser to identify the longitudinal axis of the uterus in
the case of laterally deviated uterus;
– sagittal T2-weighted fast spin-echo (FSE) sequence par-
allel to the longitudinal axis of the uterus (identified on
the previous SSFSE sequence) (TR/TE range 4675/100;
flip angle 90°; section thickness 4 mm; interslice gap
1 mm; bandwidth 41.67 kHz; FOV 32 cm; matrix 320×
224; number of averages 4; number of images 26; acqui-
sition time 3 min 49 s);
– oblique coronal T2-weighted FSE sequence parallel to
the longitudinal axis of the uterus (TR/TE range
4675/100; flip angle 90°; section thickness 4 mm;
interslice gap 1 mm; bandwidth 41.67 kHz; FOV
32 cm; matrix 320×224; number of averages 4; number
of images 26; acquisition time 3 min 49 s);
– oblique axial T2-weighted FSE sequence perpendicular
to the longitudinal axis of the uterus (TR/TE range
4675/100; flip angle 90°; section thickness 4 mm;
interslice gap 1 mm; bandwidth 41.67 kHz; FOV
32 cm; matrix 320×224; number of averages 4; number
of images 26; acquisition time 3 min 49 s);
– sagittal or axial oblique or coronal oblique fat suppressed
T2-weighted FSE sequence (TR/TE range 4675/100; flip
angle 90°; section thickness 4 mm; interslice gap 1 mm;
bandwidth 41.67 kHz; FOV 32 cm; matrix 320×224;
number of averages 4; number of images 24; acquisition
time 3 min 49 s);
– axial T1-weighted gradient-echo (GRE) sequence in-out
(chemical-shift imaging) (TR/TE 180/2,1; flip angle 80°;
section thickness 6 mm; interslice gap 0,6 mm; band-
width 62,5 kHz; field of view 38 cm; matrix 256×224;
number of averages 1; number of images 20; acquisition
time 22 s);
– axial DWI SE EPI (TR/TE 3000/74,1; flip angle 90°;
section thickness 5 mm; interslice gap 1 mm; bandwidth
250 kHz; field of view 45 cm; matrix 160×160; number
of averages 16; number of images 14; b-value 0 e 800 s/
mm2; acquisition time 1 min e 40 s);
– sagittal, coronal oblique, axial oblique T1-weighted 3D
gradient-echo liver acquisition with volume acquisition
(LAVA) sequence with fat suppression (TRe/TE range
4.4/2.1; flip angle 12°; section thickness 3.4 mm; overlap
locations −1.7 mm; bandwidth 62.5 kHz; FOV 40 cm;
matrix 320×192; number of averages 0.75; number of
images 104; acquisition time 22 s).
After i.v. administration of 0.1 mmol/kg paramagnetic con-
trast agent (Dotarem, Guerbet, Roissy, France) at a flow rate of
2 ml/s, followed by 20 ml of saline solution at the same flow
rate, the following sequences are acquired:
– dynamic sagittal T1-weighted 3D gradient-echo LAVA
with fat suppression (TR/TE range 4.4/2.1; flip angle
12°; section thickness 3.4 mm; overlap locations
−1.7 mm; bandwidth 62.5 kHz; FOV 40 cm; matrix
320×192; number of averages 0.75; number of images
104; acquisition time 22 s) acquired at 60 and 120 s after
contrast administration;
– T1-weighted 3D gradient echo LAVA fat-suppressed se-
quence, in the coronal oblique (parallel to the longitudinal
axis of the uterus), axial oblique (perpendicular to the
longitudinal axis of the uterus) and axial planes (TR/TE
range 4.4/2.1; flip angle 12°; section thickness 3.4 mm;
overlap locations −1.7 mm; bandwidth 62.5 kHz; FOV
40 cm; matrix 320×192; number of averages 0.75; num-
ber of images 104; acquisition time 22 s).
MR imaging is performed with the patient lying in the
supine position (feet first). T2-weighted FSE sequences and
DW sequences are acquired with patient breathing freely, T1-
weighted 3D gradient echo LAVA fat-suppressed sequence are
acquired in breath hold.
In case of voluminous ovarian masses that exceed the FOV
of the above-mentioned sequences, we use the following MR
protocol.
– Standard three-plane scout image;
– coronal T2-weighted SSFSE with and without fat sup-
pression (TR range/TE range 705/90; flip angle 90°; sec-
tion thickness 6 mm; interslice gap 0.6 mm; bandwidth
83.33 kHz; field of view 44–48 cm; matrix 384×224;
number of signals acquired 0.57; number of images 28;
acquisition time 24 s);
– axial T2-weighted SSFSE with and without fat suppres-
sion [time to repetition (TR)/time to echo (TE) range 765/
59; flip angle 90°; section thickness 6 mm; interslice gap
0.6 mm; bandwidth 31.25 kHz; field of view (FOV)
38 cm; matrix 320×288; number of averages 0.54; num-
ber of images 30; acquisition time 24 s];
– fast imaging employing steady-state acquisition
(FIESTA) in the coronal, axial and sagittal planes (TR
range/TE range 4/1.7; flip angle 75°; section thickness
6 mm; interslice gap 0.6 mm; bandwidth 100 kHz; field
of view 44–48 cm; matrix 320×224; number of signals
acquired 1; number of images 28; acquisition time 22 s);
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– axial DWI SE EPI [TR range/TE range 3000/74; flip
angle 90°; section thickness 8 mm; interslice gap 2 mm;
field of view 42 cm; matrix 160×160; number of signals
acquired 2; number of images 15; b-value 0 and 800 s/
mm2 that represent the best compromise between signal
to noise ratio (SNR) and lesion detection sensitivity on
our MR system; ASSET 2; acquisition time 27 s];
– sagittal, axial and coronal T1-weighted 3D gradient echo
LAVA fat-suppressed sequence (TR range/TE range 4.1/
1.9; flip angle 12°; section thickness 3.4 mm; overlap locs
−1.7 mm; bandwidth 62.5 kHz; field of view 44–48 cm;
matrix 320×192; number of signals acquired 0.70; num-
ber of images 120; acquisition time 23 s).
After i.v. administration of 0.1 mmol/kg paramagnetic
contrast agent (Dotarem, Guerbet, Roissy, France) at a
flow rate of 2 ml/s, followed by 20 ml of saline solution
at the same flow rate, the following sequences are
acquired:
– sagittal T1-weighted 3D gradient echo LAVA fat-
suppressed sequence (TR range/TE range 4.1/1.9; flip
angle 12°; section thickness 3.4 mm; overlap locs
−1.7 mm; bandwidth 62.5 kHz; field of view 44–48 cm;
matrix 320×192; number of signals acquired 0.70; num-
ber of images 120; acquisition time 23 s) acquired at 60
and 120 s after contrast administration;
– axial T1-weighted 3D gradient echo LAVA fat-
suppressed sequence (TR range/TE range 4.2/2; flip an-
gle 12°; section thickness 3.4 mm; overlap locs −1.7 mm;
bandwidth 62.5 kHz; FOV 40 cm; matrix 320×192;
number of signals acquired 0.70; number of images
120; acquisition time 23 s);
– coronal T1-weighted 3D gradient echo LAVA fat-
suppressed sequence (TR range/TE range 4.1/1.9; flip
angle 12°; section thickness 3.4 mm; overlap locs
−1.7 mm; bandwidth 62.5 kHz; field of view 44–48 cm;
matrix 320×192; number of signals acquired 0.70; num-
ber of images 120; acquisition time 23 s).
MR imaging is performed with the patient lying in the
supine position (feet first). All sequences are acquired in
breath hold.
Imaging findings
Using an imaging guided approach based on morphological




– cystic and solid;
– predominantly solid.
Then we evaluated signal intensity features (e.g.,
haemorrhagic areas, elevated protein content, fat and collage-
nous tissue) and enhancement behaviour for each lesion
(Table 4).
Unilocular cystic masses
Unilocular cystic masses in the adnexal region are more likely
benign and can have both non-ovarian or ovarian origin.
Paraovarian cysts, hydrosalpinx, pyosalpinx and
hematosalpinx are the most common extraovarian lesions,
whereas ovarian lesions are usually represented by functional
cysts and serous cystadenomas; less common unilocular ovar-
ian cystic masses are cystadenofibromas and mucinous
cystadenomas (more often multilocular). Most unilocular cys-
tic masses have low signal intensity on T1-weighted images
and high signal intensity on T2-weighted images.
Paraovarian cysts (or paratubal cysts or hydatid cysts of
Morgagni) arise from mesothelial, paramesonephric or meso-
nephric remnants. It is important to identify the ipsilateral
ovary as a separate structure in order to avoid misinterpreta-
tion; however, sometimes a Bbeak sign^ can be found [27].
Hydrosalpinx is a fluid filled fallopian tube; it may assume
a cystic appearance on some scans mimicking an ovarian le-
sion, but multiplanar visualization is usually able to demon-
strate its sausage-like C-shape or S-shape tubular structure.
Fallopian tubes can also be distended by pus or blood, respec-
tively pyosalpinx (high signal intensity on diffusion-weighted
images) and hematosalpinx (high signal intensity on T1-
weighted images) [28].
Functional cysts are the most commonly encountered cys-
tic masses in women of reproductive age as a normal part of
the menstrual cycle, including follicles (diameter <20 mm),
dominant follicles (diameter 20–25 mm), follicular cysts
(resulting from persistence of an unruptured follicle) and cor-
pus luteum cysts (resulting from a failure of the corpus luteum
to regress). The latter one may enlarge because of an internal
bleeding, showing high signal on T1-weighted images:
follow-up is able to differentiate haemorrhagic corpus luteum
cysts from endometrioma considering complete resolution of
the functional cyst.
Serous cystadenoma is a benign tumour that usually pres-
ent as an unilocular cyst with a thin regular wall (less than
3 mm); the lining is flat without internal septations, papillary
projections or solid components, showing no significative
contrast enhancement. Serous fluid shows low signal intensity
on T1-weighted and high signal intensity on T2-weighted im-
ages (Fig. 1). They are usually smaller and more often bilateral
than mucinous cystadenomas. Serous cystadenomas of
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borderline malignancy may show some small papillary
projections.
Cystadenofibroma is an uncommon benign epithelial
ovarian tumour containing both epithelial and fibrous
stromal components. This tumour may present as a purely
cystic lesion, almost indistinguishable at MRI from a
cystadenoma, although it more often shows a complex
cystic appearance with thick septa and solid components.
Foci of fibrous stroma have low signal intensity on T2-
weighted images (Figs. 2 and 3) [29–31].
Multilocular cystic masses
Multilocular cystic adnexal masses can be both benign or
borderline and are represented by endometriomas, mucinous
cystadenomas and tumours of borderline malignancy. Serous
cystadenomas may rarely be multilocular.
Endometriosis is characterized by ectopic implantation of
endometrial tissue outside the uterus, often involving the ova-
ries. Endometriotic cysts (or endometriomas or chocolate
cysts) are often multifocal and bilateral, and usually appear
as cystic to complex adnexal masses with high signal intensity
on T1-weighted and intermediate to low signal intensity on
T2-weighted images. Fat saturated T1-weighted sequences are
helpful to rule out a fat-containing lesion and to confirm the
presence of blood. On T2-weighted sequences, a gradual loss
of signal intensity is called Bshading sign^ and is caused by
repeated bleeding within the cyst. It has to be remembered that
patients with endometriosis are at risk for developing ovarian
malignancy (estimated risk about 2.5 %) [32]. Both
endometrioid and clear cell tumours may be associated with
endometriosis.
Mucinous cystadenoma is a benign mucin-containing tu-
mour, often larger than serous cystadenoma and monolateral
rather than bilateral. It usually appears as a multilocular cystic
lesion with a thin regular wall and several septations, lacking
solid components and showing no significant enhancement
after contrast administration (Fig. 4). The cystic loculi may
have variable signal intensity on both T1-weighted and T2-
weighted images, namely Bstained glass appearance^, based
on different mucin concentrations. It has to be remembered
that pseudomyxoma peritonei can result from rupture of a
mucinous cystadenoma.
Borderline tumours are a group of ovarian neoplasms his-
tologically characterized by epithelial anaplasia [33]. Com-
pared to malignant ovarian cancer, they occur in younger pa-
tients. Serous and mucinous cystadenoma account for most
borderline tumours; however, other histological types, such
as endometrioid and clear cell tumours, are sometimes seen.
These tumours usually show non-invasive behaviour, but it is
also possible for them to present with lymph node involve-
ment and peritoneal implants; however, they are associated
with a better prognosis than cystoadenocarcinomas. The mor-
phological appearance of borderline tumours is between be-
nign and malignant ones. Borderline serous cystadenoma usu-
ally manifest as a complex cystic lesion with some septa and
papillary projections (Fig. 5). Both benign and borderline mu-
cinous cystadenomas have a multilocular appearance, and it is
impossible to make a differential diagnosis at MRI (Fig. 6).
Cystic and solid masses
A mixed cystic and solid appearance of an ovarian mass
should raise a suspicion of malignancy, like surface epithelial
tumours and metastasic lesions. However, a benign lesion like
mature cystic teratoma (or ovarian dermoid cyst) also appears
as a complex mass. A germ cell tumour (Yolk sac tumour) and
sex cord-stromal tumours (granulosa cell) are also described
in this section.
Mature cystic teratoma is the most common ovarian neo-
plasm and affects mostly young patients. It is a benign germ
cell tumour consisting of at least two of the three embryogenic
germ cell layers, and usually contains ectodermal (skin, brain),
mesodermal (fat, bone) and/or endodermal (thyroid tissue,
Table 3 Classification of adnexal masses based on morphological appearance
Classification of adnexal masses basing on morphological appearance
Cystic unilocular (benign) non ovarian paraovarian cysts, hydrosalpinx, pyosalpinx and hematosalpinx
ovarian functional cysts and serous cystadenomas (common)
cystadenofibromas and mucinous cystadenomas (less common)
Cystic multilocular (benign and borderline) endometriomas, mucinous cystadenomas and borderline tumours (common)
serous cystadenomas (less common)
Cystic and solid (benign, borderline and malignant) benign mature cystic teratoma
borderline to malignant surface epithelial tumours, metastasis, Yolk sac, granulosa cell and
Sertoli-Leydig tumours
Predominantly solid (benign, borderline and malignant) benign Brenner tumour, fibrothecomas
borderline to malignant serous and mucinous carcinomas, dysgerminoma and Yolk sac
tumour, granulosa and Sertoli-Leydig cell tumours, metastasis
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gastrointestinal and bronchial epithelium) mature tissue [34].
Simultaneous presence of these components leads to a com-
plex and heterogeneous appearance; however, the key to a
correct diagnosis is detection of fat-tissue within the mass.
MRI usually demonstrates tissue with high signal intensity
both on T1-weighted and T2-weighted images and signal loss
on fat suppression sequences (Fig. 7). A T1-weighted fat-sat-
urated sequence is also able to make differential diagnosis
between fat-tissue and haemorrhagic lesions, namely endome-
trial cysts. A fat-fluid interface may also be found, and is
typical of mature cystic teratoma. Other features are areas of
low signal intensity (teeth), soft-tissue protuberances
(Rokitansky nodules) and floating debris [35]. Malignant
transformation of mature cystic teratomas is rare (1–2 % of
cases), and usually occurs in postmenopausal women due to a
squamous cell carcinoma arising from the cyst wall. In addi-
tion, it has to be known that there are other less common types
of ovarian teratomas, such as the malignant immature terato-
ma, which may have less cystic elements or be completely
solid, and the benign monodermal teratoma, in which one of
the three germ cell layers is predominant. Struma ovarii is one
of the main subtypes of ovarian monodermal teratomas
(approximately 3 % of all mature teratomas). It is mainly
composed of thyroid tissue; thus, it may be associated with
symptoms or signs of thyrotoxicosis. MRI demonstrates a
complex mass with multiple cystic and solid areas. Cystic
spaces may show variable signal intensity demonstrating both
high and low signal intensity on T1-weighted and T2-
weighted images; in particular, some cystic spaces demon-
strate low signal intensity on both T1-weighted and T2-
weighted images because of the colloid of the struma
(Fig. 8) [36, 37]. No fat-tissue can be found in this lesion.
Ovarian metastasis account for about 5 % of malignant
ovarian tumours, and there is a potential risk of misjudgment
if the primary tumour is not known. Stomach, colon, breast,
lung and contralateral ovary are the most frequent neoplasms
to metastasize to the ovaries. These tumours can spread to the
ovaries by direct invasion, transcoelomic dissemination,
hematogeneous and lymphatic spread. Krukenberg tumours
are defined as metastatic lesions to the ovary from a gastroin-
testinal cancer and characterized by mucin-producing signet-
ring cells (Fig. 9). Ovarian metastasis are more often bilateral
with a cystic and solid or a predominant solid morphological
appearance. An important enhancement of the cystic wall and
Fig. 1 Serous cystadenoma in a
64-year-old woman. (a) Sagittal
and (b) axial T2-weighted images
show a hyperintense unilocular
cystic mass (white arrows). On (c)
sagittal and (d) axial contrast-
enhanced fat-suppressed T1-
weighted images, the cyst wall
shows poor contrast enhancement
(white arrows) without
vegetations, nodularity, or solid
components
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of the solid component is usually seen after gadolinium ad-
ministration. It is very difficult to distinguish between primary
and secondary ovarian malignancy on diagnostic imaging,
mostly because of the absence of typical features helping the
differential diagnosis [38].
Surface epithelial-stromal tumours account for 65 % of all
ovarian tumours and represent 85 % of ovarian malignancies.
In this section, we describe serous cystadenocarcinoma, mu-
cinous cystadenocarcinoma, endometrioid tumours and clear
cell tumours, whereas transitional cell (Brenner) tumours will
Fig. 2 Cystadenofibroma in a
54-year-old woman. (a) Axial and
(b) coronal T2-weighted images
show a predominantly cystic mass
with small areas of fibrous stroma
along the wall characterized by
homogeneous low signal intensity
(white arrows). (c) Axial and (d)
coronal contrast-enhanced fat-
suppressed T1-weighted images
show minimum enhancement of
the cystic wall and of the fibrous
component (white arrows)
Fig. 3 Cystadenofibroma in a 29-year-old woman. (a) Axial and (b)
coronal T2-weighted images show a predominantly solid mass with
prevalence of the fibrous stroma characterized by homogeneous low
signal intensity (white arrows). (c) Axial and (d) coronal contrast-
enhanced fat-suppressed T1-weighted images demonstrate minimum
enhancement of the lesion (white arrows). (e) Photomicrograph (H&E
X30) shows that the epithelial elements are surrounded by abundant
fibrous stroma
Insights Imaging (2016) 7:21–41 31
Fig. 4 Mucinous cystadenoma in a 44-year-old woman. (a) Axial, (b)
coronal and (c) sagittal T2-weighted images show a voluminous
multilocular cystic mass with several septations. (d) Axial and (e) coronal
contrast-enhanced fat-suppressed T1-weighted images demonstrate poor
enhancement of the tumour wall and septa. (f) Photomicrograph (H&E
X400) shows cystic spaces lined by columnar cells of intestinal type with
mucinous secretion
Fig. 5 Borderline papillary-cystic serous tumour in a 43-year-old
woman. (a) Axial and (b) coronal T2-weighted images show a cystic
mass with papillary projections arising from the medial wall (white
arrows). (c) Axial and (d) coronal contrast-enhanced fat-suppressed
T1-weighted images show enhancement of the parietal solid component
(white arrows). (e) Photomicrograph (H&E X30) shows intracystic
papillary structures with fibrovascular axis
32 Insights Imaging (2016) 7:21–41
be described in the next one because of their predominantly
solid appearance.
Serous cystadenocarcinoma is the most common, and is
responsible for about 40 % of malignant ovarian neoplasms,
whereas mucinous cystadenocarcinoma is less common and
accounts for about 10 % of ovarian malignancies. These
tumours are seen as complex multilocular masses, usually
with thick and irregular walls, septations, solid components
and papillary projections of low signal intensity on T2-
weighted images with contrast enhancement after gadolinium
administration (Figs. 10 and 11). The serous fluid of the cystic
components has low to intermediate signal intensity on T1-
Fig. 6 Borderline mucinous
ovarian tumour in a 49-year-old
woman. (a) Axial T2-weighted
and (b) coronal fat-suppressed
T2-weighted images show a
multiloculated cystic ovarian
tumour with intermediate (*) to
high (white arrowheads) signal
intensity of the loculi and solid
parietal component (white
arrows). (c) Axial contrast-
enhanced fat-suppressed T1-
weighted image demonstrates
enhancement of the wall and of
the solid component (black
arrow). (d) Photomicrograph
(H&E X300) shows neoplastic
glands lined by columnar cells of
intestinal-type with mucinous
secretion
Fig. 7 Mature teratoma in a 33-
year-old woman. (a) Axial T1-
weighted, (b) axial fat-suppressed
T1-weighted, (c) sagittal T2-
weighted and (d) axial fat-
suppressed T2-weighted images
show a well-defined ovalar mass
with fat tissue (*) with high signal
intensity both on T1-weighted
and T2-weighted images and
signal loss on fat-suppressed
sequences. A hypointense nodule
(white arrowheads) is seen within
the lesion, as well as a solid
component (white arrows). (e)
Photomicrograph (H&E X20)
shows cystic space lined by
mature epidermis. Skin
appendages and neural tissue are
seen in the wall
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Fig. 8 Struma ovarii in a 32-
year-old woman. (a) Axial T2-
weighted, (b) coronal T2-
weighted and (c) axial fat-
suppressed T1-weighted images
show a predominantly solid mass
(white arrows) with multiple
cystic spaces of variable signal
intensity, some of which show
high signal intensity on T1-
weighted image (white
arrowhead). (d) Axial contrast-
enhanced fat-suppressed T1-
weighted image demonstrates
enhancement of the mass (white
arrow)
Fig. 9 Krukenberg tumour from gastric carcinoma in a 23-year-old
woman. (a) Sagittal, (b) axial and (c) coronal T2-weighted images show
a heterogeneous mass characterized by solid components with low signal
intensity (white arrows) and cystic components with high signal intensity
(white arrowheads). (d) Sagittal contrast-enhanced fat-suppressed T1-
weighted image demonstrates enhancement of the solid components
(white arrow). (e) Axial DW image (b=800 s/mm2) demonstrates in-
creased signal of the solid components of the lesion indicating
hypercellularity. (f) Photomicrograph (H&E X200) shows ovarian paren-
chyma diffusely infiltrated by signet-ring cells
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weighted and high signal intensity on T2-weighted images. In
some cases of serous cystadenocarcinoma there are
psammomatos calcifications, better seen on CT scan because
of their high attenuation. Signal intensity of mucinous content
is variable depending on mucin concentration. These tumours
can be very large, even greater than 12–15 cm. Serous
cystadenocarcinoma is more frequently bilateral than mucin-
ous cystadenocarcinoma. They may be responsible for perito-
neal invasion leading to peritoneal carcinomatosis (Fig. 12).
Endometrioid and clear cell tumours are commonly asso-
ciated with endometriosis. These tumours usually appear as
complex masses with solid and cystic components, although
they can also be predominantly cystic (Figs. 13 and 14) [39].
However, the rapid growth of an endometrioma, along with
multilocularity and presence of mural nodules within the
haemorrhagic cyst with enhancement after gadolinium admin-
istration should raise the suspicion of malignancy [32, 40].
Yolk sac tumour, also known as endodermal sinus tu-
mour, is relatively rare and is responsible for about 1 % of
ovarian malignancies. This tumour generally presents in
the second or third decade as a large mixed cystic and
solid mass with the bright dot sign, namely foci of en-
hancement due to dilated vessels (small aneurisms) as a
result of increased vascularity [41]. It is not uncommon to
find haemorrhagic areas with high signal intensity on T1-
weighted images (Fig. 15).
Fig. 10 Serous papillary
carcinoma in a 48-year-old
woman. (a) Axial, (b) sagittal and
(c) coronal T2-weighted image
show a cystic and solid mass
(white arrows). (d) Axial
contrast-enhanced fat-suppressed
T1-weighted image shows the
enhancing exophytic papillary
projections of the tumour (white
arrow). (e) Axial DW image (b=
800 s/mm2) demonstrates




cystadenocarcinoma in a 57-year-
old woman. (a) Axial, (b) coronal
and (c) sagittal T2-weighted
images show a large mass with
mixed solid and multilocular
cystic appearance with low signal
intensity of the solid component
and variable signal intensity
within the locules (Bstained glass
appearance^). (d) Axial, (e)
coronal and (f) sagittal contrast-
enhanced fat-suppressed T1-
weighted images demonstrate
marked enhancement of the solid
component, wall and septa of the
tumour
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Granulosa cell tumours are usually benign; however,
they may be malignant as well. Clinically, they can man-
ifest by producing hormones with hyperestrogenism.
Granulosa cell tumours can be divided into two main
subtypes, adult and juvenile. The adult type is responsi-
ble for about 95 % of cases and occurs preferentially in
perimenopausal and postmenopausal women, resulting in
endometrial hyperplasia and atypical bleeding. The juve-
nile type is less frequent and affects prepuberal children,
leading to pseudoprecocity. Granulosa cell tumours ap-
pear mostly as both cystic and solid masses, but they
can also have a multilocular cystic or a predominantly
solid appearance [42, 43].
Predominantly solid masses
Predominantly solid adnexal masses account for lesions with
benign, borderline and malignant behaviour. They include tu-
mours of different origin: epithelial (transitional cell –Brenner
tumour and, rarely, serous and mucinous carcinomas), germ
cell (dysgerminoma and Yolk sac tumour), sex cord
(fibrothecomas, granulosa cell tumours and Sertoli-Leydig
cell tumours) and metastatic lesions.
Brenner tumour is responsible for about 2 % of ovarian
neoplasms; it is also named Btransitional cell tumour^ be-
cause of its histological similarity to the urotelium. It is




serous cystadenocarcinoma in a
63-year-old woman. (a) Axial T2-
weighted, (b) coronal T2-
weighted, (c) axial T1-weighted,
(d) coronal T1-weighted images
show multiple tumour implants in
the left paracolic gutter (white
arrows) and omental implants
(white arrowheads in a, c). (e)
Photomicrograph (H&E X200)




adenocarcinoma in a 57-year-old
woman. (a) Axial and (b) coronal
T2-weighted images show
complex masses with solid (white
arrowheads) and cystic (white
arrows) components. On (c) axial
fat-suppressed T1-weighted
image, the cystic component
shows haemorrhagic hyperintense
signal (white arrow). On (d) axial
contrast-enhanced fat-suppressed
T1-weighted image, the solid
component shows marked
enhancement (white arrowhead).
(e) Photomicrograph (H&E X20)
shows capsular invasion by
neoplastic glands
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tumour shows a low signal intensity because of its solid
fibrous content. In some cases, areas of calcification with-
in the solid components can be found, best demonstrated
on both US and CT, rather than MRI. Brenner tumour can
be associated with other cystic tumours, like mucinous
cystadenomas, so that MRI demonstrates a lesion with
both cystic (cystadenomas) and solid (Brenner) compo-
nents [44]. Although rarely, both borderline and malignant
lesions (transitional cell carcinomas) exist with complex
cystic and solid appearances.
Dysgerminoma usually appears as a solid lobulated lesion
with fibrovascular septa, surrounded by a fibrotic capsule. The
solid component shows intermediate to high signal intensity
on T2-weighted images, whereas the septa appear at low sig-
nal intensity, but show a significant contrast enhancement
[41].
Fibromas, thecomas and fibrothecomas are classified as
sex cord-stromal tumours and are the most common benign
solid lesion of the ovaries. These tumours are usually asymp-
tomatic and there may be an association with ascites and
Fig. 14 Endometrioid
adenocarcinoma in a 60-year-old
woman. (a) Coronal and (b)
sagittal T2-weighted images
show a predominantly cystic mass
with solid component arising
from the inferior wall (white
arrowheads). (c) Axial fat-
suppressed T1-weighted image
shows hyperintense haemorrhagic
content of the cyst (*) and solid
parietal component (white
arrowhead). (d) Axial DW image
(b=800 s/mm2) demonstrates
increased signal of the solid






Fig. 15 Yolk sac tumour in a 26-
year-old woman. (a) Sagittal and
(b) axial T2-weighted images
show a mixed cystic and solid
mass (white arrows). (c) Axial
T1-weighted image shows
haemorrhagic areas with high
signal intensity within the lesion
(white arrowhead). (d) Sagittal
and (e) axial contrast-enhanced
fat-suppressed T1-weighted
images show marked
enhancement of the solid
component (white arrows).
Peritoneal fluid can also be seen
(* in a, b). (f) Photomicrograph
(H&E X200) shows endodermal
sinus pattern with Schiller-Duval
bodies; these structures are
covered by tumour cells and has a
central capillary
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pleural effusion (Meig syndrome). Fibrothecomas consist of
both fibrous tissue and theca cells with lipidic content. They
present as a well-circumscribed solid mass with low to inter-
mediate signal intensity on T1-weighted and low signal inten-
sity on T2-weighted images, although there may be some
scattered areas of cystic degeneration with high signal inten-
sity on T2-weighted scans (Fig. 16). In fibromas, the promi-
nent fibrosis with abundant collagen content is responsible for
the low signal intensity (Fig. 17), while in thecomas, the main-
ly lipidic content of theca cells may be depicted at chemical-
shift imaging [7]. After contrast administration, only a mini-
mal enhancement can be demonstrated. Differential diagnosis
of fibrothecomas includes pedunculated uterine leiomyomas;
however, the multiplanar imaging along with the absence of
the normal ipsilateral ovary are useful in distinguishing them.
Sclerosing stromal tumour is classified as sex cord-stromal
tumours into the thecoma-fibroma group. It affects mostly
young women, manifesting as menstrual irregularities. This
tumour presents as predominantly solid mass; after contrast
administration, it shows an early peripheral enhancement with
centripetal progression [43, 45, 46].
Sertoli-Leydig cell tumours account for only 0.5 % of ovar-
ian tumours; however, they can be responsible for
hyperandrogenism and are the most common virilizing tu-
mours. These tumours usually affect young women and signs
of androgen activity can be seen in about one-third of patients.
Sertoli-Leydig cell tumours usually appear as solid masses;
however, they may also present as heterogeneous lobulated
lesions with both cystic and solid components [41, 47]. On
T2-weighted images, most of these tumours show a predom-
inantly low signal intensity of the solid components, relating
to the fibrous stroma, with some scattered cystic areas of high
signal intensity (Fig. 18) [46, 48].
Conclusion
Morphological characteristics of adnexal masses range from
cystic (both unilocular and multilocular), complex (cystic and
solid) and predominantly solid. It is true that there is a certain
overlap between benign and malignant tumours; in particular,
it has to be considered that borderline lesions are very difficult
to differentiate because they have both benign and malignant
features.
In 2007, Sohaib et al. showed that from the analysis of the
MR imaging features, Bthe most predictive characteristics of
malignancy are vegetations in a cystic lesion, presence of
ascites, a maximal diameter greater than 6 cm, and necrosis
in a solid lesion^ [33]. In 2011, Valentini et al. suggested
criteria for characterization of benign and suspicious adnexal
lesions, indicating as features suggestive of malignancy the
demonstration of Bsolid, solid/cystic enhancing masses
Fig. 16 Fibrothecoma in a 66-
year-old woman. (a) Axial and
(b) sagittal T2-weighted images
show a heterogeneous solid mass
(white arrows) with low to
intermediate signal intensity.
Some areas of cystic degeneration
with high signal intensity can be
seen within the lesion (white
arrowheads). (c) Axial T1-
weighted image confirms the
solid appearance of the lesion
(white arrow). (d)
Photomicrograph (H&E X200)
shows fascicles of spindle cells
with centrally placed nuclei and a
moderate amount of pale
cytoplasm
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(greater than 4 cm in maximum diameter) with papillary pro-
jections and irregular thick wall and septa (greater than 3 mm)
into a cystic lesion^ as well as a Bheterogeneous and early
enhancement pattern^ [35].
To conclude this work, we’d like to indicate some key
imaging features and general advice that could be of help in
the differential diagnosis of adnexal masses:
– non-neoplastic lesions should always be taken into
consideration;
– in a patient with endometriosis, the presence of a complex
and rapidly growingmass with contrast enhancement should
raise the suspicion of endometrioid or clear cell tumour;
– a very low signal intensity on T2-weighted images indi-
cates a fibrotic component, suggesting a tumour of the
thecoma/fibroma group, a cystadenofibroma or a Brenner
tumour;
– sequences with fat saturation are helpful when facing a
mass with high signal intensity on T1-weighted images,
because the signal suppression is suggestive of a
Fig. 17 Fibroma in a 44-year-old
woman. (a) Axial, (b) coronal and
(c) sagittal T2-weighted images
show a polilobulated solid mass
(white arrows) with
homogeneous low signal
intensity. (d) Axial and (e)
coronal contrast-enhanced
fat-suppressed T1-weighted
images show the homogeneous
enhancement of the lesion (white
arrows). (f) Photomicrograph
(H&EX20) shows closely packed
spindle stromal cells arranged in
storiform pattern with hyaline
bands
Fig. 18 Sertoli-Leydig cell tumour in a 13-year-old woman. (a) Sagittal
and (b) axial T2-weighted images show a voluminous mixed cystic and
solid mass (white arrows). At the periphery of the mass, some signal
flow-voids that represent vascular structures are recognizable (white
arrowheads). (c) An Axial T1-weighted image shows haemorrhagic areas
with high signal intensity within the lesion (white arrow). (d) Axial
contrast-enhanced fat-suppressed T1-weighted image shows enhance-
ment of the solid component, more evident in the peripheral portion
(white arrow). (e) Photograph of the operating field shows the mass with
vascular structures on its surface (white arrowheads). (f) Photograph of
the cut surface of the resected lesion shows good MR imaging-
histopathologic correlation of the mass
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teratoma; otherwise, an endometrial cysts or other
haemorrhagic lesions should be considered;
– a Bstained glass appearance^with cystic loculi of variable
signal intensity usually refers to a mucinous tumour, be-
cause of the different mucin concentration;
– metastasis should be considered if a complex enhancing
mass is demonstrated in both ovaries (eventually looking
for an unknown primary tumour); however, it must be
remembered that serous epithelial tumours can be bilater-
al as well.
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